Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Restructuring Costs (2025)

Rocket Pharmaceuticals (RCKT) has disclosed Restructuring Costs for 1 consecutive years, with -$68000.0 as the latest value for Q4 2025.

  • Quarterly Restructuring Costs changed N/A to -$68000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at $3.2 million for FY2025, N/A changed from the prior year.
  • Restructuring Costs hit -$68000.0 in Q4 2025 for Rocket Pharmaceuticals, up from -$172000.0 in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $3.2 million in Q2 2025 to a low of -$172000.0 in Q3 2025.